article thumbnail

NHC Submits Comments on CMS Draft Guidance for IPAY 2028

Putting Patients First Blog

Inclusion of Part B Drugs: Scope, Challenges, and Opportunities The addition of provider-administered therapies covered under Medicare Part B to the IPAY 2028 cycle introduces a fundamentally different reimbursement and care delivery context than that of pharmacy-dispensed Part D drugs.

article thumbnail

Incubators and innovation hubs: Accelerating entrepreneurship in life sciences

Express Pharma

The country’s health metrics, such as the growing burden of non-communicable diseases, rising life expectancy, malnutrition, and air pollution, present a further scope for innovations in life sciences to strengthen healthcare delivery estimated to reach $60 billion by FY 2028 (1).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Reimagining Pharmacy Workforce Development: The CPA Academy

Commonwealth Pharmacists Association

Working alongside our valued member organisations, our goal is to reach over 10,000 pharmacists a year by 2028. The early-career practitioner in Ghana, using data and design tools to reshape antimicrobial use in their community. But our goals for the Academy go beyond numbers; the Academy is about genuine stories of transformation.

article thumbnail

Navigating the regulatory challenge of PFAS for pharmaceutical manufacturers

European Pharmaceutical Review

In the EU, a joint PFAS Restriction Proposal under REACH was submitted, aiming for a full ban by 2028/2030. The PFAS regulatory challenge As a result, in the EU, a joint PFAS Restriction Proposal under REACH was submitted in 2023, aiming for a full ban on all PFAS by 2028/2030. There is worldwide concern around the use of PFAS.

article thumbnail

Revolution Medicines partners Royalty Pharma on $2bn funding

Pharmaceutical Technology

The first tranche will be received by Revolution, following US Food and Drug Administration (FDA) approval of daraxonrasib to treat metastatic PDAC by January 2028. The debt facility portion consists of three tranches totalling up to $750m linked directly to daraxonrasib’s commercial milestones. Sign up for our daily news round-up!

article thumbnail

Merck agrees to acquire Verona Pharma for $10bn

Pharmaceutical Technology

Keytruda, which brought in $30bn in revenue in 2024, is approaching patent expirations set in 2028, and Merck is therefore intensifying efforts to restructure its portfolio, according to a report by Reuters. This agreement will enable the strong launch trajectory of this important medicine and provides value to Verona Pharma shareholders.”

article thumbnail

RFK Jr axes vaccine advisory committee members

Pharmaceutical Technology

Without removing the current members, the current Trump administration would not have been able to appoint a majority of new members until 2028, RFK Jr wrote. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard.